Literature DB >> 28936455

Bevacizumab in small cell lung cancer.

Giandomenico Roviello1,2, Navid Sobhani2, Daniele Generali2,3.   

Abstract

Entities:  

Year:  2017        PMID： 28936455      PMCID： PMC5599295          DOI： 10.21037/atm.2017.06.44

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

1.  Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

Authors:  Marcello Tiseo; Luca Boni; Francesca Ambrosio; Andrea Camerini; Editta Baldini; Saverio Cinieri; Matteo Brighenti; Francesca Zanelli; Efisio Defraia; Rita Chiari; Claudio Dazzi; Carmelo Tibaldi; Gianni Michele Turolla; Vito D'Alessandro; Nicoletta Zilembo; Anna Rita Trolese; Francesco Grossi; Ferdinando Riccardi; Andrea Ardizzoni
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

Review 2.  The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Authors:  Giandomenico Roviello; Thomas Bachelot; Clifford A Hudis; Giuseppe Curigliano; Andrew R Reynolds; Roberto Petrioli; Daniele Generali
Journal:  Eur J Cancer       Date:  2017-02-24       Impact factor: 9.162

3.  Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.

Authors:  Roberto Petrioli; Giandomenico Roviello; Letizia Laera; Luca Luzzi; Piero Paladini; Claudia Ghiribelli; Luca Voltolini; Ignazio Martellucci; Vincenzo Bianco; Edoardo Francini
Journal:  Clin Lung Cancer       Date:  2015-05-18       Impact factor: 4.785

4.  Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.

Authors:  Shadia Jalal; Pablo Bedano; Lawrence Einhorn; Sumeet Bhatia; Rafat Ansari; Naftali Bechar; Karuna Koneru; Ramaswamy Govindan; Jingwei Wu; Menggang Yu; Bryan Schneider; Nasser Hanna
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

5.  Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

Authors:  David R Spigel; Peter M Townley; David M Waterhouse; Liang Fang; Ibrahim Adiguzel; Jane E Huang; David A Karlin; Leonardo Faoro; Frank A Scappaticci; Mark A Socinski
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

Review 6.  Progress and challenges in the treatment of small cell lung cancer.

Authors:  Alfredo Tartarone; Pasqualina Giordano; Rosa Lerose; Maria Grazia Rodriquenz; Raffaele Conca; Michele Aieta
Journal:  Med Oncol       Date:  2017-04-29       Impact factor: 3.064

7.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

8.  Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

Authors:  Leora Horn; Suzanne E Dahlberg; Alan B Sandler; Afshin Dowlati; Dennis F Moore; John R Murren; Joan H Schiller
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 9.  Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

Authors:  Giandomenico Roviello; Daniele Generali
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

10.  Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer.

Authors:  Isabel José Dionísio de Sousa; Joana Ferreira; Joana Rodrigues; Nuno Bonito; Paula Jacinto; Mariela Marques; João Ribeiro; Ana Pais; Helena Gervásio
Journal:  ESMO Open       Date:  2016-05-17
View more
  3 in total

1.  Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.

Authors:  Ana C Carr; Amr S Khaled; Rania Bassiouni; Orielyz Flores; Daniel Nierenberg; Hammad Bhatti; Priya Vishnubhotla; J Perez Manuel; Santimukul Santra; Annette R Khaled
Journal:  Oncotarget       Date:  2017-11-25

2.  Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study.

Authors:  Keiji Sugiyama; Yoshihito Kogure; Atsushi Torii; Kazuhiro Shiraishi; Arisa Yamada; Akane Ishida; Fumie Shigematsu; Kazuki Nozawa; Hideyuki Niwa; Saori Oka; Masashi Nakahata; Chiyoe Kitagawa; Masahide Oki; Hideo Saka
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

3.  Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.

Authors:  Jing Yuan; Feng Cheng; Guodong Xiao; Xiaofeng Wang; Huijie Fan
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.